Blockchain Registration Transaction Record

BioCorRx Transitions to OTCID Market, Maintains SEC Compliance Amid Treatment Advancements

BioCorRx transitions from OTCQB to OTCID Market due to technical float requirements while maintaining SEC compliance. The company continues developing addiction and obesity treatments including LUCEMYRA and BICX104.

This news matters because BioCorRx operates in critical healthcare sectors addressing substance abuse disorders and obesity—two of the most pressing public health challenges globally. With over 16.6 million people having used methamphetamine and approximately 1 billion people worldwide affected by obesity, the company's treatment programs and pharmaceutical developments directly impact millions seeking effective interventions. The market transition represents a technical adjustment rather than operational disruption, ensuring continued access to the company's innovative approaches that combine behavioral therapy with medication-assisted treatments. For investors, the maintained SEC compliance and transparent reporting provide stability despite the quotation tier change, while patients and healthcare providers benefit from ongoing development of treatments like LUCEMYRA for opioid withdrawal and comprehensive recovery programs. In an era where addiction and obesity drive significant healthcare costs and mortality, BioCorRx's work addresses fundamental needs in treatment accessibility and effectiveness.